<DOC>
	<DOC>NCT00473616</DOC>
	<brief_summary>This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The study is sponsored by AstraZeneca.</brief_summary>
	<brief_title>Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Advanced solid tumors for which standard treatment doesn't exist or is no longer effective. Must be suitable for treatment with irinotecan Relatively good overall health other than your cancer Poor bone marrow function (not producing enough blood cells) Serious heart conditions Poor liver or kidney function Any prior anthracycline treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Phase I</keyword>
	<keyword>solid tumors</keyword>
	<keyword>solid malignancies</keyword>
	<keyword>cancer Eligibility</keyword>
</DOC>